当前位置: 首页 >> 检索结果
181. Thromboprophylaxis after Knee Arthroscopy and Lower-Leg Casting.
作者: Raymond A van Adrichem.;Banne Nemeth.;Ale Algra.;Saskia le Cessie.;Frits R Rosendaal.;Inger B Schipper.;Rob G H H Nelissen.;Suzanne C Cannegieter.; .
来源: N Engl J Med. 2017年376卷6期515-525页
The use of thromboprophylaxis to prevent clinically apparent venous thromboembolism after knee arthroscopy or casting of the lower leg is disputed. We compared the incidence of symptomatic venous thromboembolism after these procedures between patients who received anticoagulant therapy and those who received no anticoagulant therapy.
182. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
作者: Kenneth I Ataga.;Abdullah Kutlar.;Julie Kanter.;Darla Liles.;Rodolfo Cancado.;João Friedrisch.;Troy H Guthrie.;Jennifer Knight-Madden.;Ofelia A Alvarez.;Victor R Gordeuk.;Sandra Gualandro.;Marina P Colella.;Wally R Smith.;Scott A Rollins.;Jonathan W Stocker.;Russell P Rother.
来源: N Engl J Med. 2017年376卷5期429-439页
The up-regulation of P-selectin in endothelial cells and platelets contributes to the cell-cell interactions that are involved in the pathogenesis of vaso-occlusion and sickle cell-related pain crises. The safety and efficacy of crizanlizumab, an antibody against the adhesion molecule P-selectin, were evaluated in patients with sickle cell disease.
183. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
作者: Tony S Mok.;Yi-Long Wu.;Myung-Ju Ahn.;Marina C Garassino.;Hye R Kim.;Suresh S Ramalingam.;Frances A Shepherd.;Yong He.;Hiroaki Akamatsu.;Willemijn S M E Theelen.;Chee K Lee.;Martin Sebastian.;Alison Templeton.;Helen Mann.;Marcelo Marotti.;Serban Ghiorghiu.;Vassiliki A Papadimitrakopoulou.; .
来源: N Engl J Med. 2017年376卷7期629-640页
Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer. The efficacy of osimertinib as compared with platinum-based therapy plus pemetrexed in such patients is unknown.
186. Resolution of Disease Phenotypes Resulting from Multilocus Genomic Variation.
作者: Jennifer E Posey.;Tamar Harel.;Pengfei Liu.;Jill A Rosenfeld.;Regis A James.;Zeynep H Coban Akdemir.;Magdalena Walkiewicz.;Weimin Bi.;Rui Xiao.;Yan Ding.;Fan Xia.;Arthur L Beaudet.;Donna M Muzny.;Richard A Gibbs.;Eric Boerwinkle.;Christine M Eng.;V Reid Sutton.;Chad A Shaw.;Sharon E Plon.;Yaping Yang.;James R Lupski.
来源: N Engl J Med. 2017年376卷1期21-31页
Whole-exome sequencing can provide insight into the relationship between observed clinical phenotypes and underlying genotypes.
188. Prolonged Zika Virus Viremia during Pregnancy.
作者: Anna Suy.;Elena Sulleiro.;Carlota Rodó.;Élida Vázquez.;Cristina Bocanegra.;Israel Molina.;Juliana Esperalba.;María P Sánchez-Seco.;Hector Boix.;Tomás Pumarola.;Elena Carreras.
来源: N Engl J Med. 2016年375卷26期2611-2613页 195. Real-World Evidence - What Is It and What Can It Tell Us?
作者: Rachel E Sherman.;Steven A Anderson.;Gerald J Dal Pan.;Gerry W Gray.;Thomas Gross.;Nina L Hunter.;Lisa LaVange.;Danica Marinac-Dabic.;Peter W Marks.;Melissa A Robb.;Jeffrey Shuren.;Robert Temple.;Janet Woodcock.;Lilly Q Yue.;Robert M Califf.
来源: N Engl J Med. 2016年375卷23期2293-2297页 198. Screening for Babesia microti in the U.S. Blood Supply.
作者: Erin D Moritz.;Colleen S Winton.;Laura Tonnetti.;Rebecca L Townsend.;Victor P Berardi.;Mary-Ellen Hewins.;Karen E Weeks.;Roger Y Dodd.;Susan L Stramer.
来源: N Engl J Med. 2016年375卷23期2236-2245页
Babesia microti, a tickborne intraerythrocytic parasite that can be transmitted by means of blood transfusion, is responsible for the majority of cases of transfusion-transmitted babesiosis in the United States. However, no licensed test exists for screening for B. microti in donated blood. We assessed data from a large-scale, investigational product-release screening and donor follow-up program.
199. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
作者: Eric Tran.;Paul F Robbins.;Yong-Chen Lu.;Todd D Prickett.;Jared J Gartner.;Li Jia.;Anna Pasetto.;Zhili Zheng.;Satyajit Ray.;Eric M Groh.;Isaac R Kriley.;Steven A Rosenberg.
来源: N Engl J Med. 2016年375卷23期2255-2262页
We identified a polyclonal CD8+ T-cell response against mutant KRAS G12D in tumor-infiltrating lymphocytes obtained from a patient with metastatic colorectal cancer. We observed objective regression of all seven lung metastases after the infusion of approximately 1.11×1011 HLA-C*08:02-restricted tumor-infiltrating lymphocytes that were composed of four different T-cell clonotypes that specifically targeted KRAS G12D. However, one of these lesions had progressed on evaluation 9 months after therapy. The lesion was resected and found to have lost the chromosome 6 haplotype encoding the HLA-C*08:02 class I major histocompatibility complex (MHC) molecule. The loss of expression of this molecule provided a direct mechanism of tumor immune evasion. Thus, the infusion of CD8+ cells targeting mutant KRAS mediated effective antitumor immunotherapy against a cancer that expressed mutant KRAS G12D and HLA-C*08:02.
|